Loading
AL8326 is an experimental small-molecule drug from Advenchen Pharmaceuticals in phase 3 trials for small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma, with its target not yet stated publicly.
AL8326 is a small-molecule drug developed by Advenchen Pharmaceuticals and Advenchen Laboratories Nanjing. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 10mg/tablet, Oral administration, once daily. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06247605 (A Phase IIII Study of AL8326 in Small Cell Lung Cancer), in small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma. The largest, NCT06247605, plans to enrol 243 participants with primary completion expected 2028-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.AL8326 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AL8326" OR ABSTRACT:"AL8326") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AL8326, not a curated reading list.
Shares Advenchen Laboratories, Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Advenchen Laboratories and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.